Anavex life sciences corp. (AVXL)
Income statement / Yearly
Sep'19Sep'18Sep'17Sep'16Sep'15Sep'14Sep'13Sep'12Sep'11Sep'10
Operating expenses
General and administrative

6,846

5,989

5,008

8,334

4,836

2,236

-

-

-

-

Accounting and audit fees

-

-

-

-

-

-

-

139

158

151

Amortization and depreciation

-

-

-

-

-

-

-

1

1

0

Bank charges and interest

-

-

-

-

-

-

-

5

8

6

Consulting fees

-

-

-

-

-

-

-

1,155

2,757

2,082

Insurance

-

-

-

-

-

-

-

10

48

0

Investor relations

-

-

-

-

-

-

-

108

133

-

Investor relations

-

-

-

-

-

-

-

-

-

186

Legal fees

-

-

-

-

-

-

-

142

140

173

Management fees

-

-

-

-

-

-

-

0

0

0

General and administrative

-

-

-

-

-

-

1,873

9

30

39

Registration and filing fees

-

-

-

-

-

-

-

26

58

27

Rent and administration

-

-

-

-

-

-

-

0

63

12

Research and development

22,260

13,344

10,672

7,254

2,271

732

263

2,653

2,597

2,728

Total operating expenses

29,106

19,333

15,680

15,589

7,108

2,968

-

-

-

-

Salaries and wages

-

-

-

-

-

-

-

0

-

-

Travel

-

-

-

-

-

-

-

66

182

236

Website design and maintenance

-

-

-

-

-

-

-

0

0

1

Total operating expenses

-

-

-

-

-

-

-2,137

-4,321

-6,180

-5,648

Other income (expenses)
Grant income

298

149

140

141

0

0

-

-

-

-

Research and development incentive income

2,465

1,830

2,022

571

0

-

-

-

-

-

Interest income, net

207

255

88

11

-71

-7

-

-

-

-

Gain on settlement of accounts payable

115

-

-

-

-

-

-

-

-

-

Gain on settlement of accounts payable

-

-

75

151

-

-

-

-

-

-

Gain on settlement of debt

-

-

-

61

-

-

-

-

-

-

Interest income (expense), net

-

-

-

-

-

-

51

138

90

284

Gain on settlement of accounts payable

-

-

-

-

0

199

-

-

-

-

Gain on settlement of debt

-

-

-

-

0

0

-

-

-

-

Financing related charges

151

30

-

5

4,998

8,624

-

-

-

-

Accretion of debt discounts

-

-

-

-

-

-

-

98

69

1,836

Change in fair value of derivative financial instruments

-

-

-

-

-

-

-

67

100

-630

Debt conversion expense

-

-

-

-

-

-

-

0

504

0

Gain (loss) on settlement of accounts payable

-

-

-

-

-

-

-976

0

-334

-444

Financing related charges and adjustments

-

-

-

-

-

-

-480

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-3,829

-198

0

Foreign exchange gain (loss), net

-42

-49

-47

-48

70

33

-54

18

-29

61

Total other income, net

2,894

2,153

2,279

881

-4,999

-8,399

-1,562

-

-

-

Net loss before provision for income taxes

-26,212

-17,179

-13,400

-14,707

-12,108

-11,368

-

-

-

-

Income tax expense, current

82

72

59

29

0

0

-

-

-

-

Income tax benefit - deferred

-

-

-

-

-

-1,400

-

-

-

-

Net loss and comprehensive loss

-26,294

-17,252

-13,460

-14,736

-12,108

-9,968

-3,700

-8,301

-7,307

-8,783

Net Loss per share
Basic and diluted (in dollars per share)

-0.54

-0.39

-0.33

-0.42

-0.65

-

-

-

-

-

Basic (in dollars per share)

-

-

-

-

-

-1.02

-0.12

-

-

-

Diluted (in dollars per share)

-

-

-

-

-

-1.02

-0.12

-0.29

-0.29

-0.41

Weighted average number of shares outstanding
Basic and diluted (in shares)

48,906

44,655

40,841

35,153

18,584

-

-

-

-

-

Basic (in shares)

-

-

-

-

-

9,804

31,908

-

-

-

Diluted (in shares)

-

-

-

-

-

9,804

31,908

28,168

25,169

21,440